Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Success Stories

Small businesses use NCI's SBIR and STTR funding to propel their commercialization efforts. Below are stories of some NCI-funded small businesses that have successfully brought or are bringing cancer technologies from lab to market.

  • RefleXion – Biology-Guided Radiotherapy

    NCI SBIR funding supported RefleXion Medical's journey to launch its radiotherapeutic technology to treat patients with lung and bone tumors.

  • Illumina - Large-Scale Gene Sequencing

    Learn how Illumina's SBIR-funded project started from a Tuft's University spinoff that has now become a leading technology in gene sequencing as a part of a 7,300-person company with more than $3.3 billion in annual revenue.

  • Guided Therapeutics - LuViva Non-invasive Scanning Device

    Discover how SBIR-funded Guided therapeutics' Luviva can detect cervical diseases in a point-of-care setting, with the potential to replace a sizable portion of colposcopic biopsies performed to rule out cervical cancer.

  • CivaTech - CivaSheet Radiation Therapy

    Learn more about how CivaTech used NCI SBIR funding to develop low-dose-rate (LDR) radiation therapy devices to treat tumors and substantially reduce procedure time, provide homogeneous dose distribution, and minimize trauma

  • Naviscan - PET Scan Technology

    Explore how Naviscan, Inc. leveraged NCI SBIR funding to develop a flagship product, the PEM Flex® PET Scanner, which uses PET technology for the breast cancer clinical application known as positron emission mammography, PEM.

Email